The AZ Respiratory & Immunology Pipeline—pushing the boundaries of What Science Can Do?

  • 14 Apr 2026
  • 7:00 PM - 8:00 PM
  • Virtual

Registration


Register


Join us on Tuesday, April 14th from 7PM-8PM for an invite only Discussion with AstraZeneca!


As we navigate the next frontier of medical innovation, we are sending this invitation to a select group of leaders for a confidential deep dive into our emerging assets and strategic clinical milestones. This is a rare opportunity to engage directly with the visionaries shaping our portfolio before they reach the broader market.

Why Attend?

  • Unrivaled Insights: Gain first-hand knowledge of late-stage developments and upcoming data readouts. 
  • Direct Dialogue: Participate in a high-level exchange with speaker Robert Fogel, M.D.
  • Strategic Foresight: Preview the scientific breakthroughs that will define the healthcare landscape over the next decade.

The Details

Strict Confidentiality: Please note that this session is by invitation only. The information shared is sensitive and intended solely for the invited participants.

  • Title: The AZ Respiratory & Immunology Pipeline—pushing the boundaries of What Science Can Do?
  • Speaker: Robert Fogel, MD
  • Date: April 14, 2026 from 7:00PM-8:00PM
  • Location: Virtual link will be sent to confirmed attendees.
  • Description: Robert Fogel, M.D., will share on update on the AZ short- and medium-term pipeline in Respiratory and Immune Mediated Diseases.  This will include our understanding of how treatment paradigms may evolve, the role of precision medicine, and emerging modalities beyond classic small molecules and injectable biologics that have the potential to break the efficacy barrier in these diseases of high unmet need.

About the Speaker:

Robert Fogel, MD is currently the Vice President Respiratory and Immunology (R&I) for US Medical, at AstraZeneca.

Robert earned his MD degree from Columbia University and continued both his Internal Medicine residency and Pulmonary/critical care medicine fellowship at Harvard Medical School - Mass General Hospital. He built a distinguished career in the industry, holding numerous senior leadership positions across Global Medical Affairs, R&D and Global commercial functions over the last decade. Prior to this role, Robert served as AstraZeneca's VP, R&I for Global BioPharmaceuticals Medical (BPM). He brings a wealth of experience having developed and launched several inhaled and biologic medicines.

Prior to joining AstraZeneca, Robert worked at Novartis, where he held positions including the Head of Medical Affairs for Gene Therapies, and the Head of Global Medical Affairs for the Respiratory and Allergy franchise. 


RSVP is required by April 10, 2026 to secure your seat. 


Powered by Wild Apricot Membership Software